


## PHARMACEUTICAL 2023

## Viking Therapeutics Inc. Rank 107 of 446







## PHARMACEUTICAL 2023



## Viking Therapeutics Inc. Rank 107 of 446

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of Viking Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 145% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	167,040
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,947
Liabilities, Non-Current	1,260
Other Assets	1,489
Other Compr. Net Income	-553
Other Expenses	0
Other Liabilities	0
Other Net Income	1,488
Other Revenues	0
Property and Equipment	0
Research and Development	54,234
Selling, General and Administrative Expense	16,121

Output Variable	Value in 1000 USD
Assets	168,529
Liabilities	23,207
Expenses	70,355
Revenues	0
Stockholders Equity	145,322
Net Income	-68,867
Comprehensive Net Income	-69,144
Economic Capital Ratio	189%

